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U1 snRNP (U1), in addition to its splicing role,
protects pre-mRNAs from drastic premature termi-
nation by cleavage and polyadenylation (PCPA) at
cryptic polyadenylation signals (PASs) in introns.
Here, a high-throughput sequencing strategy of
differentially expressed transcripts (HIDE-seq) map-
ped PCPA sites genome wide in divergent organ-
isms. Surprisingly, whereas U1 depletion terminated
most nascent gene transcripts within 1 kb,
moderate functional U1 level decreases, insufficient
to inhibit splicing, dose-dependently shifted PCPA
downstream and elicited mRNA 30 UTR shortening
and proximal 30 exon switching characteristic of acti-
vated immune and neuronal cells, stem cells, and
cancer. Activated neurons’ signature mRNA short-
ening could be recapitulated by U1 decrease and
antagonized by U1 overexpression. Importantly, we
show that rapid and transient transcriptional upregu-
lation inherent to neuronal activation physiology
creates U1 shortage relative to pre-mRNAs. Addi-
tional experiments suggest cotranscriptional PCPA
counteracted by U1 association with nascent tran-
scripts, a process we term telescripting, ensuring
transcriptome integrity and regulating mRNA length.INTRODUCTION
Messenger RNAs (mRNAs) in eukaryotic cells are produced from
precursor transcripts (pre-mRNAs) by posttranscriptional pro-
cessing. In metazoans, two processing reactions—splicing of
introns and alternate cleavage and polyadenylation—are partic-
ularly extensive and contribute most significantly to mRNA tran-
scriptome diversity (Di Giammartino et al., 2011; Hartmann and
Valca´rcel, 2009; Wang et al., 2008). Splicing is performed by
a spliceosome that assembles on each intron and predominantly
comprises small nuclear RNPs (snRNPs), U1, U2, U4, and U5,
and U6 snRNPs in equal stoichiometry (Nilsen, 2003; Wahl
et al., 2009). U1 snRNP (U1) plays an essential role in defining
the 50 splice site (50ss) by RNA:RNA base pairing via U1 snRNA’s50 nine nucleotide (nt) sequence. Using antisense morpholino
oligonucleotide complementary to U1 snRNA’s 50 end (U1
AMO) that interferes with U1 snRNP’s function in human cells,
we observed accumulation of introns in many transcripts, as
expected for splicing inhibition (Kaida et al., 2010). However, in
addition, the majority of pre-mRNAs terminated prematurely
from cryptic polyadenylation signals (PASs) in introns, typically
within a short distance from the transcription start site (TSS).
These findings indicated that nascent transcripts are vulnerable
to premature cleavage and polyadenylation (PCPA) and that U1
has a critical function in protecting pre-mRNA from this poten-
tially destructive process. We further showed that PCPA sup-
pression is a separate, splicing-independent and U1-specific
function, as it did not occur when splicing was inhibited with
U2 snRNA AMO or the splicing inhibitor, spliceostatin A (SSA)
(Kaida et al., 2007).
These observations were made by transcriptome profiling
using partial genome tiling arrays, which provided limited infor-
mation. Here, to define the parameters involved in PCPA and
its suppression, we devised a strategy (HIDE-seq) to select
and sequence only differentially expressed transcripts, identi-
fying changes that occur upon U1 decrease to various levels
and in different organisms. The sequence information obtained
from HIDE-seq provided genome-wide PCPA maps, and these,
together with direct experiments, revealed that U1’s PCPA
suppression is not only essential for protecting nascent tran-
scripts but is also a global gene expression regulation mecha-
nism. Unexpectedly, PCPA position varied widely with the
degree of U1 decrease, trending to usage of more proximal
PASs with greater reduction. This yielded mRNAs with shorter
30 untranslated regions (30 UTRs) and alternatively spliced iso-
forms resulting from usage of more proximal alternative polyade-
nylation (APA) sites, which is characteristic of activated immune,
neuronal, and cancer cells (Flavell et al., 2008; Mayr and Bartel,
2009; Niibori et al., 2007; Sandberg et al., 2008). We demon-
strate that U1 decrease can recapitulate such specific mRNA
changes that occur during neuronal activation. Indeed, we
show that the rapid transcriptional upregulation during neuronal
activation is a physiological condition that creates U1 shortage
relative to nascent transcripts. Furthermore, U1 overexpression
inhibits activated neurons’ mRNA signature shortenings. We
suggest that by determining the degree of PCPA suppression,
U1 levels play a key role in PAS usage and hence mRNA length.
We propose a model whereby U1 binds to nascent pre-mRNAsCell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc. 53
cotranscriptionally to explain how U1 shortage results in a corre-
sponding loss of distal PASs suppression from the cleavage and
polyadenylation machinery that is associated with the RNA poly-
merase II (polII) transcription elongation complex (TEC) (Das
et al., 2007; Hirose and Manley, 1998; McCracken et al., 1997).
RESULTS
HIDE-Seq: A Strategy for High-Throughput Sequencing
of Only Transcriptome Differences
To identify transcriptome changes after U1 snRNP functional
depletion, complementary DNA (cDNA) libraries were prepared
from poly(A) RNA of human cells (HeLa) 8 hr after transfection
with 15 nmol of U1 AMO (U1 depleted) or control AMO (Kaida
et al., 2010). Each cDNA library was digested separately with
three 4 bp restriction endonucleases to produce fragments of
uniform length (250 bp), and different adaptor oligonucleotides
were ligated separately to the 50 ends of the experimental cDNA
for subsequent amplification. Subtractive hybridization and
suppression PCR selectively amplified only the differentially
expressed transcripts (Diatchenko et al., 1996; Gurskaya et al.,
1996). Nested primers fused to 454 sequencer linkers, and
sample-specific barcodes were used to generate amplicons of
subtracted libraries prepared in both U1-control and control-
U1 directions for massive parallel sequencing in the same well,
controlling for sample-to-sample variation (Figure 1A). The recip-
rocal sequence reads from bidirectional subtraction further
enhanced the definition of transcriptome changes.
High-throughput amplicon sequencing was performed by
using only 1/4–1/2 of a 454 sequencing plate (300,000 reads)
for extensive profiling (Table S1 available online). Nearly 70%
of HIDE-seq reads, averaging 150–400 nt, were unambiguously
mapped (90% identity/90% coverage) to the genome (Table S1).
Reads located in intergenic regions and sequences not unique to
either of the subtraction directions were excluded from further
analysis. Only a minor fraction (0.03%) was from ribosomal
RNA as compared to >70% without subtraction, confirming the
efficiency of the method and indicating that the majority of reads
are informative (Table S1). Importantly, as more reads were
obtained, the number of new affected genes discovered pla-
teaued (Figure 1B), as did coverage within a gene (data not
shown), suggesting that extensive coverage was achieved and
allowing a lack of reads to indicate little or no sequence change
at a given location.
Data from high-density genomic tiling arrays (GTA) of human
chromosomes 5, 7, and 16 for HeLa cells treated with U1 AMO
under the same conditions used here (15 nmol) provided
a comprehensive data set with which to compare the HIDE-
seq methodology (Kaida et al., 2010). HIDE-seq reads present
at a given genomic locus were interpreted as being up or down
in U1 AMO-treated cells relative to control, according to whether
they came from the U1-control (red) or the control-U1 (green)
subtraction, respectively (Figure 1C). For GTA, we used SSA
as a reference for intron accumulation (e.g., NSUN2 and
SKIV2L2) and to facilitate discovery of PCPA, represented by
50 intron accumulation that terminates abruptly, followed by
a decrease in downstream signals (e.g., RFWD3 and CUL1).
HIDE-seq readily identified the same transcriptome changes as54 Cell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc.GTA (Figure 1C). Sorted for chromosomes 5, 7, and 16, it
captured the highly significant (R2 fold change, R 100 nt,
p < 0.01) intron accumulations detected by GTA in 85%
(189/223) of the genes (Figure S1A), which is a very high corre-
spondence considering that RNAs came from separate biolog-
ical experiments. HIDE-seq discovered 198 additional genes
with intron accumulation on these same three chromosomes,
82%of which were confirmed by lower-stringency GTA analysis,
indicating that HIDE-seq is highly reliable and sensitive. More-
over, HIDE-seq identified these and other differences genome
wide, capturing subtle sequence changes such as exon skipping
(Figures S1B and S1C). Although HIDE-seq is not quantitative
or necessarily complete, it represents an alternative and comple-
mentary approach to full transcriptome sequencing, providing
a detailed snapshot of transcriptome differences at a fraction
of the cost. Combined with a streamlined informatics pipeline
we developed (http://www.med.upenn.edu/dreyfusslab), HIDE-
seq is a simple and powerful strategy that is widely applicable
with different sequencing platforms (e.g., Illumina; data not
shown).
PCPA and Its Suppression by U1 Are Evolutionarily
Conserved
We used HIDE-seq to determine whether PCPA occurs in diver-
gent organisms following U1 depletion in mouse (3T3) and
Drosophila (S2) cells (Figure 1B) with AMOs specific to each
organism’s U1 50 end sequence. As in humans, premature termi-
nation in introns was U1 snRNP specific and was not a conse-
quence of splicing inhibition (Figures S1E and S1F). HIDE-seq
in HeLa, 3T3, and S2 detected sequence differences in 6,548,
5,724, and 3,283 genes, respectively, which could be classified
into several patterns (Figure 2B). Accumulation of polyadeny-
lated intron reads, followed by a decrease in downstream exon
signals, provided the most direct evidence for PCPA (Figures
2A, S2, S3, and S4). This pattern, designated as Z (Figure 2B),
demonstrated that PCPA typically occurred in intron 1 with little
or no transcription beyond that point. We developed an algo-
rithm to detect Z and related patterns, designated as L and 7,
which represent PCPA events, but either the upstream accumu-
lation or the downstream decrease, respectively, was not de-
tected (Figure 2B). It is likely that differential stability of the
various transcripts produced determines whether a Z, 7, or L
pattern is observed. Collectively, these accounted for 40% of
the changes. In addition, other patterns consistent with PCPA
were detected, such as all exons down (e.g., Figure 1C;
SKIV2L2), likely resulting from very early PCPA, although the
possibility of transcriptional downregulation cannot be excluded.
Several genes with all introns up (e.g., Figure 1C; NSUN2) also
had polyadenylated intronic reads, indicating that these, too,
do not entirely escape PCPA. Another pattern, 30 L, representing
a major class at moderate U1 decrease as discussed later, is
similar to L, but the down reads (i.e., control-U1 direction) are
near the 30 end of the gene, which is indicative of transcript short-
ening. Together, these patterns account for 75%–90% of the
transcriptome changes in U1 depleted cells, and their remark-
able similarity in the three organisms indicates that PCPA and
U1’s function in its suppression are essential for formation of
full-length transcripts for the majority of metazoan genes.
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Figure 1. HIDE-Seq Identifies Genome-wide Transcriptome Changes
(A) Unsubtracted and subtracted libraries prepared in both directions (control-U1, green; U1-control, red) are shown (left gel) along with possible products of
suppression PCR. Differentially expressed sequences are in red or green and common sequences are in black. Nested PCR (right gel) was performed with
primers containing barcodes (hashed lines) and 454 adaptors A and B (yellow and light blue).
(B) Randomly sampled reads with greater than 90% coverage and 90% identity were plotted against affected genes for HeLa, NIH/3T3, and S2 from individual or
combined (gray) subtractions.
(C) HIDE-seq reads are above (U1-control [UP]) and below (control-U1 [DOWN]) gene structures in black (block, exon; thin block, UTR; horizontal line, intron).
Spliced reads are connected by colored dashed lines, whereas immediately adjacent reads separated by RsaI, HaeIII, and AluI sites are not. Log2 fold changes
from GTA of U1 AMO or SSA-treated HeLa cells normalized to controls (bottom). Yellow and open arrows point to inferred PCPA sites.
See also Table S1 and Figure S1.Moderate U1 Decrease Elicits 30 UTR Shortening
and a Switch to Shorter mRNA Isoforms
The sequencing data from complete U1 depletion indicated that
PCPA occurred 10–30 nt downstream of cryptic PASs that are
similar to PASs found at the 30 end of transcripts (Hu et al., 2005)
(Figures 2A and S2–S4). These included both canonical
(AAUAAA or AUUAAA) and rare or not previously described
hexamers (Beaudoing et al., 2000; Tian et al., 2005), as well as
U-rich and GU-rich elements that typically surround PASs. To
identify PASs that may be particularly vulnerable to PCPA and
to assess the relevance of U1’s suppression under less drastic
conditions, we decreased U1 levels by 25% and 50%, with0.25 and 1.0 nmol U1 AMO, respectively (Kaida et al., 2010).
Moderate U1 decreases differed from those observed in U1
depletion in three major ways (Figure 2B). First, significantly
fewer genes were affected (35%–50% compared to 15 nmol;
Figure 2B). Second, there was no general intron accumulation,
indicating that splicing was not inhibited (Figure 2B; e.g., all
introns up, Z, or 7). Third, and most surprisingly, moderate U1
decrease shifted the PCPA positions toward much greater
distances from the TSS. Representative examples of the major
patterns from various U1 level decreases are shown in Figure 2C.
The majority of changes at the moderate U1 decrease showed
a 30 L pattern, reflecting decreases near the ends of genesCell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc. 55
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Figure 2. Transcriptome Profiles Show a Conserved Function of U1 snRNP in PCPA Suppression
(A) HIDE-seq profiles are shown along with sequences of poly(A) reads (location indicated by solid arrows) aligned to the genome for S2, NIH/3T3, and HeLa.
Distance (nt) is relative to the upstream 50ss with the PAS hexamer likely used and stretches of A’s added to HIDE-seq reads in red. See also Figures S2–S4.
(B) Illustrations of patterns observed (depicted above each column; e.g., Z: red up then green down) after U1 AMO, and the percentage of each category was
reported for Drosophila (15), mouse (15), and human at three doses (15, 1.0, and 0.25) compared to the total number of affected genes in parenthesis. Introns,
solid red boxes; exons, empty boxes.
(C) Individual examples of patterns described in Figure 2B are shown with brackets indicating results from more than one concentration. Solid arrows indicate
reads ending in poly(A) tails; open arrows are inferred PCPA; red triangles are documented PASs. See also Figures S5 and S6.
(D) Using reads with poly(A) tails terminating in introns (Figures S2–S5; Table S2), the distribution of distances of PCPA relative to the TSS are plotted for
Drosophila and mouse (top) and human at high and low U1 AMO (bottom).(e.g., IMPDH2) and consisted mostly of decreases in distal
30 UTR reads (e.g., EIF2S3 and Figures S5 and S6), suggesting
30 UTR shortening in genes of a wide range of sizes. A wide-
spread shift to usage of more proximal PASs in introns in the 30
half of genes (e.g., SHFM1) was also observed. Many of the
genes at 0.25 nmol U1 AMO that had shorter 30 UTR (e.g.,
NDUFA6) also had several exon signals upregulated (Figure 2B),
possibly due to elimination of microRNA (miRNA) targets in the 30
UTR (Bartel, 2009). The CD44 gene (Figure 2C) illustrates the
PCPA continuum and its U1 dose dependence, having a shorter
30 UTR at 0.25, an L pattern at 1.0, and a Z pattern from PCPA in56 Cell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc.the first intron at 15, which suggests usage of more proximal
PASs in the same gene with further decrease of U1.
The overall change in PCPA position with the degree of U1
level decrease is illustrated in Figure 2D. Upon U1 depletion in
three organisms, most PCPA occurred1 kb from the TSS, typi-
cally in the first (48%) or one of the first introns (intron 2, 26%;
intron 3, 11%). However, at lower U1 decreases, PCPA occurred
at much greater distances from the TSS (20 kb) (Figure 2D,
bottom, Figure S5, Table S2). In most, if not all cases, including
transcripts that terminated within 1 kb from the TSS, several
strong predicted PASs, and many more noncanonical PASs
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Figure 3. Moderate U1 Reduction-Induced PCPA Regulates Expression of Short Isoforms
(A) HIDE-seq profile for GABPB1 at high and low U1 AMO is above diagrams of long (blue) and short (red) isoforms. RT-qPCR of short and long isoforms was
performed on cDNA from cells transfected with a range of U1 AMO concentrations by using a common forward and different reverse primers as indicated (blue
arrows). Gray dotted boxes indicate region of transcript probed. Ratios of short to long are reported above histograms.
(B) UBAP2L was probed by RT-PCR for short (due to 30 exon switching) and long isoforms (gels) and by RT-qPCR on cDNA from cells treated with various AMOs.
Green triangle, 30ss and PAS AMOs; black arrows, poly(A) reads; open arrows, inferred PCPA.
Error bars represent SD.were bypassed before the site of PCPA. Importantly, many of the
PCPA sites coincided precisely with previously reported polya-
denylated expressed sequence tags (ESTs) from a wide range
of cell types and tissues (Figures S2 and S5), suggesting that
PCPA is a natural phenomenon that occurs under normal phys-
iological conditions.
Loss of U1 PAS Suppression Promotes Alternative
Splicing of Proximal 30 Terminal Exons
Two types ofmRNAchanges resulting fromPCPAat lowU1AMO
(human 1.0 and 0.25) were detected, in addition to 30 UTR short-
ening (Figure S6). First, PCPA in introns produced shorter
mRNAs that lack the downstream exons and 30 UTR of the full-
length transcript. In some of these, the open reading frame
(ORF) of the alternative terminal exon could potentially extend
into the intron (Figure 3A), a scenario referred to as a ‘‘composite’’
or ‘‘bleeding’’ exon (Tian et al., 2007). Quantitative RT-PCR
on RNA of cells transfected with a range of U1 AMO doses
confirmed the shift to proximal polyadenylation predicted by
HIDE-seq (Figure 3A). As expected, upon U1 depletion, both
short and long isoforms decreased due to early PCPA or splicing
inhibition, indicated by the Z patterns (e.g., GABPB1 2.5 and
15 nmol). At low U1 AMO, however, rather than an overall tran-
script level decrease, the amounts of the short forms remained
relatively stable whereas the long forms decreased, causing
the ratio of the short to the long isoform to increase (Figure 3A).
A second type of polyadenylated read found in introns of the
canonical transcript at low U1 AMO (solid arrows) mapped tothe ends of exons that can be alternatively spliced mutually
exclusively with the full-length gene’s terminal exon (‘‘short’’
in Figure 3), an example of splicing-dependent APA (Edwalds-
Gilbert et al., 1997; Zhang et al., 2005). The UBAP2L gene
(Figure 3B) displayed a dose-dependent increase in the relative
amount of the shorter isoform at lowU1 AMO (RT-PCR gel inset).
Interestingly, many 30 exon switching cases, including UBAP2L,
have been reported following immune cell activation and sug-
gested to result from alternative splicing (Sandberg et al.,
2008). However, we considered an alternative mechanism,
in which PCPA occurs first, and that it is this event that causes
the upstream 50ss to splice to an alternative 30ss not utilized in
the full-length transcript. To address this, we used AMOs to
block either the 30ss or the PAS of the short isoform and
measured the levels of both isoforms by RT-qPCR (Figure 3B).
As expected, the 30ss AMO caused a switch to the long isoform
by blocking alternative splicing. Interestingly, the PAS AMO
also caused the level of the short isoform to drop drastically,
whereas the long isoform doubled (Figure 3B; PAS AMO). Taken
together, these data suggest that loss of U1 suppression of
a PAS determines alternative splicing to a mutually exclusive
terminal exon.
PCPA and Its Suppression Is a 50–30 Directional Process
HIDE-seq provided information on PCPA position in introns,
revealing that it occurred in all three organisms at a median
distance of 500–1,000 nt from the nearest 50ss (Figure 4A, blue
plot) but at variable and usually much greater distances fromCell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc. 57
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Figure 4. U1 Bound outside the 50ss Is Required to Suppress PASs >1 kb Away
(A) Distribution of the log10 distance at which PCPA occurredwasmeasured in each organism from the start of the poly(A) tail back to the upstream 5
0ss (light blue)
or downstream to the 30ss (yellow). See also Figures S2–S4 and Table S2.
(B) Arrows indicate multiple PCPA sites per gene.
(C) HeLa cells were transfected with WT NR3C1 minigene (lane 1) or one containing a 50ss mutation (lanes 2–12) and increasing amounts of mutant U1 that base
pairs to one of four locations along the pre-mRNA (above in blue). PCPA in the intron was detected by 30 RACE, and RT-PCR of exon 2 served as the loading
control. Percent suppression (PCPA to exon 2 ratio) was normalized to lane 2.
(D) Control or U1 AMO were transfected along with WT NR3C1 minigene (lanes 1 and 2) or NR3C1, in which the PAS1 [385 nt] sequence in the intron was
duplicated (PAS2) and placed 1,295 nt downstream of the 50ss. Minigenes in which the 50ss (lanes 3 and 4), PAS1 (lanes 5 and 6), or both (lanes 7 and 8) were
mutated are indicated. 30 RACE was performed as in (C).
(E) Control, U1, or an AMO to the 50ss of the endogenous BASP1 gene were transfected as indicated. PCPA at the PAS 3.5 kb downstream of exon 1 was
measured by 30 RACE. RT-PCR on intronic sequences upstream (IR1) and downstream (IR2) of the PAS is shown.the nearest 30ss (Figure 4A, yellow plot) (Figures S2–S4, Table
S2). In each organism, we found cases of multiple PCPA sites
within the same intron (e.g., Spen, RBM39) or same transcript
(e.g., Spen, Slc38a2), demonstrating that there are several
actionable PASs along a transcript (Figure 4B), and it is likely58 Cell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc.that U1 bound at the 50ss and elsewhere in introns is required
to suppress them.
To probe PCPA mechanism, we investigated whether a
splicing-defective U1 can suppress PCPA by using NR3C1mini-
gene constructs (Figure 4C) (Kaida et al., 2010). The wild-type
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Figure 5. Moderate U1 Reduction Recapitu-
lates Isoform Switching upon Neuronal
Activation
(A and B) Rat PC12 (A) and mouse MN-1 (B)
neurons were stimulated with forskolin or
forskolin/KCl for 3 hr or separately transfectedwith
control AMO or increasing amounts of U1 AMO.
RT-PCR detecting short and long forms of
homer-1/vesl-1 and dab-1 is shown with histo-
grams depicting the ratio of S/L. Gray dotted
boxes indicate the region of transcript probed,
blue arrows show primer locations, and G6PDH is
a loading control.(WT) minigene (lane 1) splices properly, whereas a 50ss mutation
causes PCPA 385 nt into intron 2 (lane 2). PCPA was completely
suppressed by a 50 end-mutated U1 complementary to the 50ss
(mutU1/B). Varying degrees of suppression were observed also
for U1s tethered elsewhere to the intron and upstream exon both
in the vicinity of the cryptic PAS (45%–80%) and by increasing
WT U1. This suggests that U1 can suppress PCPA even without
being able to function in splicing and that U1 bound upstream
does so more efficiently (e.g., mutU1/A and mutU1/C). We next
constructed an NR3C1 minigene in which the actionable PAS
in intron 2 was duplicated (Figure 4D). Transfection of this
construct with U1 AMO (lane 2) caused PCPA at the first PAS
(PAS1; 385 nt) and, as previously reported, a 50ss mutation
caused PCPA (lane 3), but more occurred from this PAS in the
presence of U1 AMO (lane 4) (Kaida et al., 2010). When PAS1
was mutated, PCPA now occurred from the second PAS
(PAS2) located 1,295 nt from the 50ss, indicating that a down-
stream PAS(s) is also vulnerable and that PCPA occurs with
50 to 30 directionality. When both the 50ss and PAS1 were
mutated, some PCPA occurred from PAS2 (lane 7), indicating
that protection from the 50ss extends out to PAS2, but again
U1 AMO elicited more PCPA (lane 8), suggesting that additional
PCPA suppression is provided by U1 bound to sequences other
than the 50ss.
To address how far beyond a 50ss U1 snRNP’s PCPA suppres-
sion extends, we studied the endogenous BASP1 gene, which is
PCPAed relatively far from the 50ss, 3.5 kb into the first intron
(Figure 4E). Interestingly, little or no PCPA occurred with
a 50ss-blocking AMO (lane 3), whereas cotransfection with the
50ss AMO and U1 AMO (lane 4) resulted in a substantial amount,
suggesting that suppression by U1 from the 50ss alone is insuffi-
cient. Additional controls confirmed that the 50ss AMO was
effective in inhibiting splicing (lanes 2–4: mRNA decreases and
IR1 increases), and a cryptic 50ss was not activated (Figure 4E).
We conclude that, at a distance of 3.5 kb, a PAS is outside the
protective range of 50ss-bound U1. Taken together, the HIDE-
seq data and direct probing demonstrate the 50 to 30 direction-
ality of the PCPA process and strongly suggest a need for U1
in excess of what is required for splicing.Cell 150,U1 Decrease Recapitulates Isoform
Shortening in Activated Neurons
Examples consistent with the transcript
shortening we describe have been char-
acterized in activated neurons, particu-larly the homer-1/vesl-1 gene, which plays a critical role in syn-
aptogenesis. Neuronal activation results in a rapid shift (<6 hr)
in the processing of the pre-mRNA encoding homer-1, from
a full-length (L) to a shorter mRNA (S). Homer-S is produced
by an extension of exon 5 and APA in the downstream intron
to delete the C-terminal-encoding exons (Niibori et al., 2007).
Using rat PC12 cells, we show by RT-PCR that a range of low
U1 AMO (0.25–0.5 nmol) dramatically increased the S form
and caused a reciprocal dose-dependent decrease in homer-
L, mirroring the switch seen upon neuronal activation with for-
skolin and KCl (Figure 5A). This shift in ratio of S/L (histogram)
was evident even at 0.1 nmol, corresponding to an estimated
10% decrease in U1. Further U1 decrease (1.0–4.0 nmol)
caused both forms to disappear, likely as a result of PCPA
shifting closer to the TSS. In addition to homer-1, activity-
dependent shortening of many other proteins critical for synap-
togenesis has been described, including Dab1 (Flavell et al.,
2008). Indeed, in mouse MN-1 cells, Dab1 also displayed
a similar isoform shift with U1 decrease (Figure 5B). Our results
suggest that U1 levels can regulate the size of mRNA isoforms
produced from many genes.
Transcriptional Upregulation in Activated Neurons
Creates U1 Shortage
Two possible scenarios could potentially explain the shift to
usage of more proximal PASs in activated cells if this was indeed
due to loss of U1 PCPA suppression. Either U1 levels decreased
or the amount of nascent transcripts that it needs to protect
increased. To explore these possibilities under physiological
conditions, we determined the amount of U1 and pre-mRNAs
during neuronal activation (Figure 6A). Comparing control to
activated PC12 cells, U1 (yellow) was quantified by RT-qPCR,
and nascent transcripts (green) were pulse labeled with
5060-3H uridine for 30 min before RNA isolation and poly(A)
RNA selection, followed by scintillation counting to determine
the ratio of nascent mRNA to total RNA. This revealed a robust
increase in transcriptional output of about 40%–50% at 2–4 hr
postactivation, whereas U1 levels did not change, creating
a significant U1 shortage relative to its targets. This gap returned53–64, July 6, 2012 ª2012 Elsevier Inc. 59
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Figure 6. U1 Ratio to Pre-mRNA Determines Immediate-Early
Polyadenylation Switch
(A) PC12were activatedwith forskolin/KCl ormock treated (dimethyl sulfoxide,
DMSO) for the indicated times and labeled with 3H-uridine for 30 min prior to
collection. Ratios of nascent transcripts (green) to total RNA were determined
by scintillation and normalized to amounts of unlabeled total RNA. DMSO
controls represent the average of six time points per experiment, and activated
values represent the average of two independent experiments (3 hr time point
measured once). U1 snRNA (yellow) was measured by RT-qPCR at the same
time points.
(B) PC12 cells were transfected overnight (24 hr) to overexpress U1 (or empty
vector) and activated with forskolin/KCl. Homer-1 isoforms were probed by
RT-PCR 3 hr after activation, as in Figure 5A. Histograms depict the ratio of S/L
forms from biological repeat experiments with percent U1 overexpression
reported below.
Error bars represent SD.to baseline at 8 hr, providing a built-in window of opportunity for
rapid global gene expression regulation in response to external
stimuli. Notably, Homer-S amounts coincided with the U1
shortage window, rising sharply after activation, peaking at
2–4 hr (10 fold increase), and returning to near-baseline levels
at 6–8 hr. In contrast, the predominant form, Homer–L, remains
mostly unchanged upon activation (data not shown).60 Cell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc.U1 Overexpression Inhibits mRNA Shortening in
Activated Neurons
Although the U1 shortage creates an opportunity for proximal
PASs to be used, the switch to shorter isoforms may not neces-
sarily result specifically from loss of U1’s function. To address
this, we asked whether U1 overexpression could counteract
the switch from Homer-L to Homer-S in activated neurons.
PC12 cells were transfected with increasing amounts of a U1
snRNA expression vector or an empty vector 24 hr prior to acti-
vation. Exogenously expressed U1 quantified by RT-qPCR
showed that overexpression (40% of endogenous U1) pre-
vented the homer-1 switch to the Homer-S isoform in a dose-
dependent manner (Figure 6B). This suggests a role for U1
PCPA suppression in the neuronal activation pathway and
demonstrates that altering U1 levels regulates gene expression.
DISCUSSION
Partial genome tiling arrays previously showed that U1 protec-
tion is necessary to prevent drastic premature termination of
the majority of nascent pol II transcripts by PCPA from cryptic
PASs scattered throughout introns (Kaida et al., 2010). We refer
to this activity as telescripting, as it is necessary for nascent tran-
scripts to extend over large distances. Here, a rapid and versatile
high-throughput strategy for identifying transcriptome changes,
HIDE-seq, and experiments based on the wealth of information it
provided yielded a much greater definition of U1 telescripting,
revealing that it is not only an evolutionarily conserved measure
for ensuring transcriptome integrity but also a robust mechanism
for gene expression regulation. Surprisingly, PCPA position in
a given gene varied depending on the amount of available U1.
Whereas U1 depletion inhibited splicing and caused PCPA, typi-
cally in the first intron, moderate U1 decreases (10%–50%) did
not inhibit splicing but caused PCPA farther downstream, trend-
ing toward greater distances from the TSS with lesser U1
decrease. Significantly fewer but still numerous genes were
affected by moderate U1 decrease compared to U1 depletion,
and it was nondestructive, producing shorter mRNAs due to
usage of alternative, more promoter-proximal PASs rather than
the normal PAS at the 30 end of the full-length gene. Thus, tele-
scripting can be modulated by decreasing available U1 over
a large range without splicing being compromised, which is
consistent with the idea that there is an excess of U1 over
what is required for splicing.We suggest that telescripting serves
as a global gene-expression regulation mechanism.
Our data demonstrate that the predominant transcriptome
changes resulting from incomplete telescripting are various
forms of mRNA shortening, including 30 UTR shortening and
PCPA in introns. Thus, telescripting plays a major role in deter-
mining mRNA length and isoform expression. Indeed, several
mRNAs of different lengths can be produced from the same
gene by PCPA, corresponding to the degree of U1 decrease
(e.g., Figure 3, GABPB1, UBAP2L). Importantly, PCPA can
profoundly modulate protein expression levels and isoforms.
Although 30 UTR shortening would not change the sequence of
the encoded protein, it removes elements, such as microRNA-
and hnRNP-protein-binding sites, that could be critical for the
mRNA’s regulation, including its stability, localization, and
translational efficiency (Filipowicz et al., 2008; Huntzinger and
Izaurralde, 2011). In contrast, PCPA in introns would produce
an mRNA that encodes a protein lacking the C terminus or con-
taining a new C-terminal peptide, if the ORF extends into the
terminal intron. An additional scenario associated with intronic
PCPA is 30 exon switching, also referred to as splicing-depen-
dent APA, which reflects the general view that mechanistically,
alternative splicing determines the PAS that is utilized. However,
we showed that AMO masking of the alternative terminal exon’s
PAS prevented its splicing, indicating that splicing into the alter-
native terminal exon depended on PCPA from this PAS (Fig-
ure 3B). Thus, PCPA can direct 30 exon switching, revealing an
unexpected splicing-independent role for U1 in alternative
splicing regulation.
Several lines of evidence strongly suggest that U1 telescript-
ing is a physiological phenomenon. First, over the entire range
of U1 AMOs we used, numerous PCPA sites coincided precisely
with previously detected polyadenylated transcripts, indicating
that these cryptic sites are utilized naturally. These include
ESTs representing short mRNA isoforms from a wide range
of specimen (Figures S2 and S5), of which some have been
noted as APA from proximal PASs (Lou et al., 1996; Pan et al.,
2006; Tian et al., 2007). Second, many of the mRNA shortening
events resulting from loss of PCPA suppression are indistin-
guishable from the widespread mRNA shortening observed in
activated T lymphocytes and neurons, proliferating cells, and
cancer cells (Flavell et al., 2008; Mayr and Bartel, 2009; Sand-
berg et al., 2008; Zhang et al., 2005). Notably, 33% of the
genes that undergo 30 UTR shortening in activated T cells
(Sandberg et al., 2008) are similarly affected by low U1 AMO
in HeLa cells (data not shown), as are RAB10 and CCND1
(Figures 2C and S6), which are seen in cancer cells (Mayr
and Bartel, 2009). Third, moderate U1 decrease recapitulated
precisely hallmark switches to shorter isoforms in a neuronal
activation model. Using native inducers (KCl and forskolin), we
have shown that U1 decrease alone causes the same isoform
switching in both homer-1 and Dab-1 in a dose-dependent
manner. Representing the best-characterized example, the
homer-1 gene switches to an isoform lacking the C-terminal
domain-encoding exons, which antagonizes the full-length
protein’s critical activity in synapse strengthening and long-
term potentiation (Sala et al., 2003).
Having relied in our studies on deliberate U1 downregulation,
we considered whether there are physiological circumstances
under which U1 levels could become deficient. Given U1’s abun-
dance and very long half-life (Sauterer et al., 1988), it seemed
unlikely that its levels would significantly decrease in absolute
terms in the short time frame in which mRNA shortening is
observed. We considered an alternative scenario whereby U1
shortage relative to the targets it needs to protect in nascent
transcripts could arise simply by an increase in transcriptional
output of pre-mRNAs. Supporting this scenario, our measure-
ments showed a rapid and transient increase in nascent tran-
scripts of 40%–50% upon neuronal activation, whereas U1
levels showed little, if any, change (Figure 6A). This creates
a significant U1 shortage relative to nascent pre-mRNAs, the
magnitude of which is in the same range of the AMO experi-
ments. This transcription-driven gap, detectable at 2–4 hr andreturning to baseline at 6–8 hr after activation, creates a window
of opportunity for APA to occur from proximal PASs due to the
transient decrease in telescripting capacity. Importantly, the
switch to shorter isoforms during neuronal activation could
be antagonized by U1 overexpression in a dose-dependent
manner. These data provide further evidence that U1 PCPA
suppression is a built-in PAS selection mechanism and thus
plays a major role in regulating gene expression during neuronal
activation and potentially in response to other physiological
stimuli.
The mechanism and factor(s) involved in the mRNA short-
ening in diverse activation conditions have not been identified
(Flavell et al., 2008; Ji and Tian, 2009; Mayr and Bartel, 2009;
Sandberg et al., 2008). However, the remarkable similarities
they have with U1 shortage suggest that they also involve loss
of U1 telescripting, at least during the initial (immediate/early)
phase. Other factors have been described that could also cause
a shift to proximal alternative PASs, particularly upregulation
of general polyadenylation and 30 end processing factors such
as Cstf64 (Chuvpilo et al., 1999; Takagaki et al., 1996). How-
ever, this requires new protein synthesis and takes many (>18)
hours (Shell et al., 2005) and therefore cannot explain the rapid
switch to a proximal PAS, in contrast to U1 shortage, which is
immediate upon stimulation and occurs even in the presence
of protein synthesis inhibition (data not shown) (Loebrich and
Nedivi, 2009). The potential role of U1 and other factors at later
times after cell activation and in other cells remains to be deter-
mined. Other means of creating U1 shortage, without transcrip-
tion increase, can be envisioned, such as its sequestration in
nuclear structures or by expression of other RNAs to which it
could bind.
We propose a model for U1 telescripting that could explain
its role in mRNA length regulation and isoform switching (Fig-
ure 7). We suggest that PCPA occurs cotranscriptionally by
the same machinery that carries out normal 30 end cleavage
and polyadenylation in the terminal exon of the full-length
gene and is a byproduct of the coupling between transcription
and this downstream process (Calvo and Manley, 2003; Danto-
nel et al., 1997; McCracken et al., 1997). Cleavage and polya-
denylation (CPA) factors associate with the pol II TEC (Glover-
Cutter et al., 2008; Hirose and Manley, 1998) close to the TSS
and are therefore poised to process newly transcribed PASs
with favorable sequence and structural features (actionable
PASs) that it encounters throughout most of the length of the
gene. This is normally prevented by U1 snRNP that binds to
the nascent transcript. Previous studies have shown that U1
can inhibit polyadenylation of the normal PAS when tethered
in its proximity in the terminal exon and in vitro (Ashe et al.,
2000; Fortes et al., 2003; Gunderson et al., 1998; Vagner
et al., 2000). U1 is recruited to nascent pol II transcripts,
including intronless transcripts, by multiple interactions with
the pre-mRNA and RNA processing factors, as well as the tran-
scriptional machinery (Brody et al., 2011; Das et al., 2007;
Lewis et al., 1996; Lutz et al., 1996). In all three organisms
we studied, PCPA was typically not detected in the first few
hundred nucleotides, rising sharply thereafter and peaking 1
kb from the TSS (Figure 2D). It is possible that actionable
PASs upstream of this point are not utilized because CPACell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc. 61
Figure 7. A Proposed Model of Cotranscriptional
PCPA and Its Suppression by U1
Cleavage and polyadenylation factors (CPSF) associate
with pol II TEC and are thus poised for 30 end cleavage and
polyadenylation but can also cause premature termination
(PCPA) from cryptic PASs found throughout pre-mRNAs.
U1 is recruited to nascent transcripts by multiple interac-
tions, including base pairing of its 50 end with cognate pre-
mRNA sequences (50 ss and other) and can suppress
PCPA by inhibiting the pol II associated CPSF over <1 kb
range. U1 shortage increases the probability of distal
PASs remaining unprotected.factors may have not yet associated with the TEC (Mayer et al.,
2010; Mueller et al., 2004), which depends on pol II’s carboxyl
terminal domain phosphorylation state (Buratowski, 2009). We
suggest that this lag could serve (and may have evolved) to
allow U1 binding before transcripts are exposed to CPA to
prevent their early destruction. Consistent with this distance
from TSS consideration, PASs in the 50 UTR that are not
PCPAed are functional when placed at the 30 end of the gene
(Guo et al., 2011).
Our data also indicated that 50ss-bound U1 has a limited
protective range of up to 500–1,000 nt and therefore would
be insufficient to ensure telescripting through larger introns.
Complete PCPA suppression could not be provided by U1
from the 50ss alone, even within this perimeter, and plays almost
no role in protecting more distal PASs, depending instead on
additional U1 bound in introns (Figures 4D and 4E). Indeed,
introns contain numerous U1 binding sites that do not function
as 50ss, which we suggest serve to anchor U1 to protect introns
from PCPA. Furthermore, we found that U1 with a mutated 50
sequence that cannot function in splicing can still function in tele-
scripting (Figure 4C), supporting the notion of two separate U1
roles. U1’s capacity to interact with nascent transcripts directly,
even without base pairing (Patel et al., 2007; Spiluttini et al.,
2010), enhances its association throughout the pre-mRNA, al-
lowing it to scan the transcript and accelerate the rate with which
it can find more stable base pairing sites, including the 50ss.
Importantly, PAS mutations cause PCPA from downstream in-
tronic PASs (Figure 4D), suggesting a directional process, which
is consistent with a cotranscriptional mechanism. We propose
that U1 shortage causes transcript shortening because, as co-
transcriptional recruitment of U1 to nascent transcripts becomes
limiting, it leaves distal PASs less protected, providing a built-in62 Cell 150, 53–64, July 6, 2012 ª2012 Elsevier Inc.and U1 dose-dependent mechanism for mRNA
length regulation and isoform switching.
EXPERIMENTAL PROCEDURES
Cell Treatments
HeLa, NIH/3T3, and S2 cells were transfected by electro-
poration using a Genepulser (Bio-Rad) or Nucleofector
(Amaxa) with control or antisense morpholino (AMO) to
U1 at 0.25, 1.0, and 15 nmol for 8 hr as described (Kaida
et al., 2010). HeLa transfection with gene-specific AMOs
(15 nmol/7.5 mM) to PASs, 50, and 30ss was performed
in the same manner. All AMO sequences synthesized
by Gene Tools are listed in Table S3. SSA treatment was100 ng/ml for 8 hr. PC12 and MN-1 cells were stimulated with 20 mM forskolin
and/or 50 mM KCl for 3 hr (Impey et al., 1998) or transfected with U1 AMO for
8 hr by Amaxa Nucleofector.
HIDE-Seq Library Preparation
Subtracted cDNA libraries were prepared by using Clontech’s PCR-Select
cDNASubtraction Kit (Diatchenko et al., 1996; Gurskaya et al., 1996; Lukyanov
et al., 1995) with several modifications listed below. Poly(A) RNA was reverse
transcribed with random hexamers and custom oligo(dT) primers containing
blunt end restriction sites to prepare individual cDNA pools. Following second
strand synthesis, double-stranded (ds) cDNAs were each digested separately
withRsaI,HaeIII, orAluI to produce independent libraries of the same samples.
Each sample (control AMO or U1 AMO) served as the tester or the reference
(i.e., forward and reverse subtractions). Ligation of adaptors, hybridization,
and primary PCR (Figure 1A, left gel) steps were as described and detailed
in the Extended Experimental Procedures. Nested PCR (Figure 1A, right gel)
was performed on each library with primers containing 454 adaptors, barco-
des, and linker molecules listed in Table S3. Forward and reverse libraries
were multiplexed, subjected to emulsion PCR, and bidirectionally sequenced
using Titanium 454 chemistry.
Genomic Tiling Arrays, RT-PCR, Real Time, and 30 RACE
Arrays were performed in triplicate for human chromosomes 5, 7, and 16
(Kaida et al., 2010). All primers, RNA preparation methods, conditions, and
cell types are listed in the Extended Experimental Procedures. mRNA isoform
and U1 snRNA levels determined by qPCR were normalized to G6PDH and 5 s
rRNA, respectively.
Minigene, Mutant U1 Transfections, and U1 Overexpression
The NR3C1 minigene and the 50ss and PAS mutations contained therein have
been described (Kaida et al., 2010). To duplicate the PAS, the NR3C1 plasmid
EcoRV-StuI fragment was reinserted into the original minigene at the EcoRV
site. Modification of U1’s 50ss-binding domain and plasmid concentrations
are listed in the Extended Experimental Procedures. 30 rapid amplification of
cDNA ends (RACE) products were digested with HindIII to distinguish PCPA
and mRNA bands. PC12 were transfected with U1 snRNA in a pSiren-RetroQ
expression vector (Clontech) driven by the native U1 promoter. RT-qPCR
using probes specific for a 1 bp difference in transfected U1was used to deter-
mine the extent of overexpression.
Tritiated Uridine Labeling of mRNA
PC12 cells were pulsed with 50 mCi of 5060-3H uridine in 500 ml media with
0.04 mg/ml actinomycin D for 30 min before collecting. Total RNA was isolated
by Trizol, and poly(A) RNA was selected on Oligotex beads (QIAGEN). Radio-
activity in each fraction was determined by scintillation counts, and ratios of
mRNA to total RNA were normalized to the concentration of total RNA deter-
mined on a Nanodrop spectrophotometer.
HIDE-Seq Data Analysis
A description of read alignments, the development of an algorithm to describe
patterns found by HIDE-seq, the identification of poly(A) reads, and the calcu-
lation of density plots are in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2012.05.029.
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